Flatiron Health

Power in the information age: inside our mission to learn from the patient experience
To improve lives by learning from the experience of every cancer patient.
Flatiron offers industry-leading cloud-based software and services for community oncologists
We’ve built real-world datasets for a number of malignancies

- Advanced Gastric Cancer
- Advanced Head and Neck Cancer
- Advanced Melanoma
- Advanced Non-Small Cell Lung Cancer
- Advanced Urothelial Carcinoma
- Chronic Lymphocytic Leukemia
- Diffuse Large B-Cell Lymphoma
- Early Breast Cancer
- Hepatocellular Carcinoma
- Mesothelioma
- Metastatic Breast Cancer
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Cancer
- Metastatic Prostate Cancer
- Metastatic Renal Cell Carcinoma
- Multiple Myeloma
- Ovarian Cancer
- Small Cell Lung Cancer
Published with Flatiron Data

Source

- OTHER TUMORS
- MELANOMA
- PAN-TUMOR
- PROSTATE
- BONE METS
- NSCLC

Process

- 41+
- 61

Validation

- OTHER TUMORS
- BREAST
- COLORECTAL
- MELANOMA
- CLL
- MULTIPLE MYELOMA
- NSCLC

Independent, partner authored using Flatiron data
Flatiron-authored (Including collaborators)

Additional Details on Flatiron Publications
How are others applying Flatiron RWE?

Commercial Applications

- Understanding uptake of new therapies in specific subpopulations

Research Applications

- Understand reasons for discontinuation of current standards of care
- Outpatient health resource utilization useful for CEA based on RWD
- Understand correlation between treatment sequence and survival outcomes

Regulatory Applications

- Submission of Real-World Outcomes for label expansion opportunities
Many Are Looking at Different Parts of the Same Problem
Clinical Drug Trials May Be Coming to Your Doctor’s Office

Electronic medical records make possible a new research model based on real-world evidence.

By Amy Abernethy and Sean Khozin
Sept. 12, 2017 6:56 p.m. ET
**Patient Journey**

- **Diagnosed with Stage II NSCLC**
- **Undergoes surgery for early-stage disease**
- **Develops metastatic disease**
- **Tested for EGFR and ALK**
- **Progresses on 1L, tested for PD-L1 and re-tested for EGFR**
- **Starts 1L therapy**
- **Starts 2L therapy, deteriorates and is hospitalized**
- **Death**
Be your own advocate. How do you want your story told?